10x Genomics Inc Quick Ratio (TXG) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
10x Genomics Inc   (NASDAQ: TXG)

10x Genomics Inc 's Quick Ratio

TXG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 4.66 below 10x Genomics Inc average.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Quick Ratio than 10x Genomics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 665 to 848.

Explain Quick Ratio?
How much Cash & cash equivalents TXG´s has?
What are TXG´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TXG Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 25.31 % 19.08 % 65.66 % 47.92 % 159.15 %
Y / Y Cash & cash equivalent Change 23.43 % 26.46 % 33.05 % 21.08 % 17.67 %
Quick Ratio MRQ 4.66 4.75 3.41 3.27 4.73
TXG's Total Ranking # 848 # 665 # 264 # 691 # 610
Seq. Current Liabilities Change 4.32 % -25.97 % 4.16 % 55.77 % -0.86 %
Seq. Cash & cash equivalent Change 2.26 % 3.14 % 8.57 % 7.79 % 4.77 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 6
Healthcare Sector # 321
Overall Market # 848


Quick Ratio Statistics
High Average Low
15.72 6.19 2.78
(Sep 30 2019)   (Jun 30 2020)




Financial Statements
10x Genomics Inc 's Current Liabilities $ 119 Millions Visit TXG's Balance sheet
10x Genomics Inc 's Cash & cash equivalent $ 552 Millions Visit TXG's Balance sheet
Source of TXG's Sales Visit TXG's Sales by Geography


Cumulative 10x Genomics Inc 's Quick Ratio

TXG's Quick Ratio for the trailling 12 Months

TXG Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 39.42 % 57.02 % 50.31 % 41.69 % 33.4 %
Y / Y Cash & cash equivalent TTM Growth 25.91 % 24.65 % 21.78 % 13.69 % 11.22 %
Quick Ratio TTM 3.94 3.92 3.83 4.07 4.36
Total Ranking TTM # 3680 # 2727 # 1557 # 2772 # 2970
Seq. Current Liabilities TTM Growth 4.7 % 3.71 % 14.15 % 12.49 % 17.92 %
Seq. Cash & cash equivalent TTM Growth 5.26 % 6.01 % 7.43 % 5.04 % 4.2 %

Quick ratio ranking by company, industry and sector >> Back to TXG Financial Strength Comparisons >> Go to Compare TXG Quick Ratio to its Competitors

On the trailing twelve months basis TXG Cash & cash equivalent grew by 23.43 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in 10x Genomics Inc 's Quick Ratio to 3.94, above TXG average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Laboratory Analytical Instruments industry 21 other companies have achieved higher Quick Ratio than 10x Genomics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2727 to 3680.

Explain Quick Ratio?
How much Cash & cash equivalents TXG´s has?
What are TXG´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Laboratory Analytical Instruments Industry # 22
Healthcare Sector # 869
Within the Market # 3680


trailing twelve months Quick Ratio Statistics
High Average Low
6.36 3.84 2.17
(Mar 31 2020)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Laboratory Analytical Instruments Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Alamar Biosciences Inc   8.94 $ 250.052  Millions$ 27.960  Millions
Eyepoint Inc   7.80 $ 327.214  Millions$ 41.943  Millions
Astrotech Corp  5.02 $ 11.334  Millions$ 2.257  Millions
Scientific Industries Inc   4.92 $ 7.882  Millions$ 1.602  Millions
Standard Biotools Inc   4.75 $ 270.026  Millions$ 56.802  Millions
10x Genomics Inc   4.66 $ 552.058  Millions$ 118.509  Millions
Pacific Biosciences Of California Inc   3.44 $ 236.873  Millions$ 68.806  Millions
Cytek Biosciences Inc   2.83 $ 262.004  Millions$ 92.698  Millions
Quanterix Corporation  1.86 $ 93.529  Millions$ 50.373  Millions
Nautilus Biotechnology Inc   1.52 $ 13.166  Millions$ 8.639  Millions
Rapid Micro Biosystems Inc   1.13 $ 20.500  Millions$ 18.150  Millions
Bionano Genomics Inc   1.04 $ 10.420  Millions$ 10.039  Millions

Date modified: 2026-09-26T07:37:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.